Jung, Klaus

[["dc.bibliographiccitation.firstpage","1467"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","1478"],["dc.bibliographiccitation.volume","79"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Raus, Ismene"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Schueler, Phillip"],["dc.contributor.author","Herrmann, Markus Karl"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:57:35Z"],["dc.date.available","2018-11-07T08:57:35Z"],["dc.date.issued","2011"],["dc.description.abstract","Purpose: To test for a possible correlation between high-grade acute organ toxicity during primary radiochemo-therapy and treatment outcome for patients with anal carcinoma. Methods and Materials: From 1991 to 2009, 72 patients with anal carcinoma were treated at our department (10 patients had stage I, 28 patients had stage II, 11 patients had stage IIIA, and 13 patients had stage IIIB cancer [Union Internationale Contre le Cancer criteria]). All patients received normofractionated (1.8 Gy/day, five times/week) whole-pelvis irradiation including iliac and inguinal lymph nodes with a cumulative dose of 50.4 Gy. Concomitant chemotherapy regimen consisted of two cycles of 5-fluorouracil (1,000 mg/m(2)total body surface area (TBSA)/day as continuous intravenous infusion on days 1-4 and 29-32) and mitomycin C (10 mg/m(2)/TBSA, intravenously on days 1 and 29). Toxicity during treatment was monitored weekly, and any incidence of Common Toxicity Criteria (CTC) grade of for skin reaction, cystitis, proctitis, or enteritis was assessed as high-grade acute organ toxicity for later analysis. Results: We found significant correlation between high-grade acute organ toxicity and overall survival, locoregional control, and stoma-free survival, which was independent in multivariate analysis from other possible prognostic factors: patients with a CTC acute organ toxicity grade of >= 3 had a 5-year overall survival rate of 97% compared to 30% in patients without (p < 0.01, multivariate analysis; 97% vs. 48%,p = 0.03 for locoregional control, and 95% vs. 59%, p = 0.05 for stoma-free survival). Conclusions: Our data indicate that normal tissue and tumor tissue may behave similarly with respect to treatment response, since high-grade acute organ toxicity during radiochemotherapy showed itself to be an independent prognostic marker in our patient population. This hypothesis should be further analyzed by using biomolecular and clinical levels in future clinical trials. (c) 2011 Elsevier Inc."],["dc.identifier.doi","10.1016/j.ijrobp.2010.01.010"],["dc.identifier.isi","000288980100027"],["dc.identifier.pmid","20605354"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23433"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1879-355X"],["dc.relation.issn","0360-3016"],["dc.title","HIGH-GRADE ACUTE ORGAN TOXICITY AS A POSITIVE PROGNOSTIC FACTOR IN PRIMARY RADIOCHEMOTHERAPY FOR ANAL CARCINOMA"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","662"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Annals of Otology Rhinology & Laryngology"],["dc.bibliographiccitation.lastpage","669"],["dc.bibliographiccitation.volume","118"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Blomeyer, Barbara D."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T11:24:31Z"],["dc.date.available","2018-11-07T11:24:31Z"],["dc.date.issued","2009"],["dc.description.abstract","Objectives: Treatment methods for patients with cervical cancer of an unknown primary site (CUP) are still under discussion. The purpose of this retrospective study was to analyze the oncological follow-up of 58 patients treated for cervical CUP. Methods: From 1986 to 2006, 58 patients with cervical CUP were treated at the authors' institution. Treatment consisted of neck dissection alone in 8, irradiation or chemoradiation in 5, combined surgery and radiotherapy in 28, and surgery and radiochemotherapy in 17. Results: The 3-year and 5-year overall survival rates for all patients were 52.9% and 40.9%, respectively. The 3-year and 5-year disease-specific Survival rates were 50.9% and 39.7%, respectively. The 3-year and 5-year neck control rates were 73.7% and 67.3%, respectively. Neck dissection followed by radiochemotherapy was associated with the best 3-year and 5-year locoregional control rates. Extracapsular extension was a predictor of survival, but not of neck control. Distant metastases developed in about one third of all patients and were the most frequent cause of tumor-related death in cases of advanced neck disease. Conclusions: Despite the fact that regional control can be achieved in many cases, survival rates may be limited by distant metastasis, especially in patients with advanced neck disease."],["dc.identifier.isi","000270190000010"],["dc.identifier.pmid","19810608"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56424"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Annals Publ Co"],["dc.relation.issn","0003-4894"],["dc.title","Impact of Distant Metastasis in Patients With Cervical Lymph Node Metastases From Cancer of an Unknown Primary Site"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","864"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Radiology"],["dc.bibliographiccitation.lastpage","871"],["dc.bibliographiccitation.volume","258"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Daldrup, Benjamin"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:58:48Z"],["dc.date.available","2018-11-07T08:58:48Z"],["dc.date.issued","2011"],["dc.description.abstract","Purpose: To test for an association between high-grade acute organ toxicity during adjuvant radiation and chemotherapy and treatment outcome in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Materials and Methods: Institutional review board approval was obtained for this retrospective study. From September 1994 to October 2008, 294 HNSCC patients were treated with adjuvant radiation and chemotherapy at the authors' department. They received normofractionated (2 Gy per fraction) irradiation to include associated nodal drainage sites, for a cumulative dose of 60-64 Gy. From January 2002 to December 2009, 91 patients received additional concomitant cisplatin-based chemotherapy. Toxicity during treatment was monitored weekly according to the common toxicity criteria (CTC); any CTC toxicity grade 3 or higher, including mucositis, dysphagia, or skin reaction, was considered high-grade acute organ toxicity. The influence of possible prognostic factors on overall survival and locoregional control was studied by means of uni- and multivariate Cox regression. Results: A statistically significant association was found between high-grade acute organ toxicity and both overall survival and locoregional control. Patients with CTC grade 3 or greater acute organ toxicity had a 5-year overall survival and locoregional control rate of 90% and 97%, respectively, as compared with 24% and 74%, respectively, in patients without such toxicity (P < .01). Multivariate analyses revealed that this association was independent from other factors that may influence treatment toxicity, especially concomitant chemotherapy and/or radiation therapy. Conclusion: The data suggest that normal tissue and tumor tissue may behave similarly with respect to treatment response, as high-grade acute organ toxicity during radiation and chemotherapy was associated with better outcomes in the patient population; therefore, the hypothesis should be further analyzed on the biomolecular and clinical level and with other tumor entities in prospective clinical trials. (C)RSNA, 2011"],["dc.identifier.doi","10.1148/radiol.10100705"],["dc.identifier.isi","000287573100023"],["dc.identifier.pmid","21339350"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23729"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Radiological Soc North America"],["dc.relation.issn","0033-8419"],["dc.title","High-Grade Acute Organ Toxicity as Positive Prognostic Factor in Adjuvant Radiation and Chemotherapy for Locally Advanced Head and Neck Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","186"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Herrmann, M. K. A."],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Jung, K."],["dc.contributor.author","Strehle, J."],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Hermann, Robert Michael"],["dc.date.accessioned","2018-11-07T08:43:03Z"],["dc.date.available","2018-11-07T08:43:03Z"],["dc.date.issued","2010"],["dc.format.extent","24"],["dc.identifier.isi","000278071200058"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19860"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","16th Annual Meeting of the German-Society-of-Radio-Oncology"],["dc.relation.eventlocation","Magdeburg, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","Hormone status and quality of life in men after multimodal curative therapy (neoadjuvant chemoradiotherapy, TME and adjuvant chemotherapy) locally advanced rectum."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","5640"],["dc.bibliographiccitation.lastpage","5640"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Wolff, Hendrik A."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ried, Thomas"],["dc.contributor.author","Ghadimi, Michael"],["dc.date.accessioned","2022-06-08T07:57:08Z"],["dc.date.available","2022-06-08T07:57:08Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1158/1538-7445.AM10-5640"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110007"],["dc.notes.intern","DOI-Import GROB-575"],["dc.publisher","American Association for Cancer Research"],["dc.relation.conference","Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC"],["dc.title","Abstract 5640: KRAS and BRAF in rectal cancer treated with preoperative chemoradiotherapy"],["dc.type","conference_paper"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","874"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.lastpage","880"],["dc.bibliographiccitation.volume","189"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Wolff, Cornelia R."],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Jung, K."],["dc.contributor.author","Sennhenn-Kirchner, Sabine"],["dc.contributor.author","Hinterthaner, Marc"],["dc.contributor.author","Mueller-Dornieden, Annegret"],["dc.contributor.author","Koerber, Wolfgang"],["dc.contributor.author","Marten-Engelke, K."],["dc.contributor.author","Roedel, Ralf M. W."],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Engelke, C."],["dc.date.accessioned","2018-11-07T09:19:18Z"],["dc.date.available","2018-11-07T09:19:18Z"],["dc.date.issued","2013"],["dc.description.abstract","Background and purpose. Patients treated for squamous cell carcinoma of the head and neck (HNSCC) carry a high risk of second primary malignancies (SPM). Recently, computed tomography (CT) of the chest was shown to significantly decrease the risk of death due to bronchial carcinoma (BC) in a cohort of smokers whose risk of BC is increased but might be lower than that of patients previously treated for HNSCC. Thus, the present study evaluated the potential benefit of CT and other examinations in the detection of SPM in HNSCC patients. Patients and methods. Between July 2008 and November 2011, 118 participants underwent a prospective, systematic examination for SPM (13 women, 105 men, median age 62 years). All patients had been previously treated for HNSCC and showed no recurrence or distant metastases at the time of the study start. CT scans, ear-nose-throat endoscopy, and endoscopy of the esophagus and stomach were performed. Results. Overall, 33 suspicious findings were clarified by additional investigations. In all, 26 SPM were confirmed in 21 of 118 patients (18%; 10 lung, 7 HNSCC, 3 gastrointestinal, 1 renal). Eighteen of these 21 patients (86%) underwent therapy with curative intent. Conclusion. The examinations revealed a high prevalence of curable stage SPM in HNSCC patients. Adapting a surveillance scheme including a chest CT is recommended."],["dc.identifier.doi","10.1007/s00066-013-0404-4"],["dc.identifier.isi","000326077500008"],["dc.identifier.pmid","23842636"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28601"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","1439-099X"],["dc.relation.issn","0179-7158"],["dc.title","Second primary malignancies in head and neck cancer patients High prevalence of curable-stage disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","30"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.lastpage","35"],["dc.bibliographiccitation.volume","186"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Hermann, Robert Michael"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Schirmer, Markus"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Herrmann, Markus Karl Alfred"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Christiansen, Hans"],["dc.date.accessioned","2018-11-07T08:48:37Z"],["dc.date.available","2018-11-07T08:48:37Z"],["dc.date.issued","2010"],["dc.description.abstract","Purpose: To test for a possible correlation between high-grade acute organ toxicity during preoperative radiochemotherapy and complete tumor regression after total mesorectal excision in multimodal treatment of Locally advanced rectal cancer. Patients and Methods: From 2001 to 2008, 120 patients were treated. Preoperative treatment consisted of normofractionated radiotherapy at a total dose of 50.4 Gy, and either two cycles of 5-fluorouracil (5-FU) or two cycles of 5-FU and oxaliplatin. Toxicity during treatment was monitored weekly, and any toxicity CTC (Common Toxicity Criteria) grade 2 of enteritis, proctitis or cystitis was assessed as high-grade organ toxicity for later analysis. Complete histopathologic tumor regression (TRG4) was defined as the absence of any viable tumor cells. Results: A significant coherency between high-grade acute organ toxicity and complete histopathologic tumor regression was found, which was independent of other factors Like the preoperative chemotherapy schedule. The probability of patients with acute organ toxicity >= grade 2 to achieve TRG4 after neoadjuvant treatment was more than three times higher than for patients without toxicity (odds ratio: 3.29, 95% confidence interval: [1.01, 10.96]). Conclusion: Acute organ toxicity during preoperative radiochemotherapy in rectal cancer could be an early predictor of treatment response in terms of complete tumor regression. Its possible impact on local control and survival is under further prospective evaluation by the authors' working group."],["dc.description.sponsorship","German Research Foundation (DFG) [KFO 179]"],["dc.identifier.doi","10.1007/s00066-009-2037-1"],["dc.identifier.isi","000273623400005"],["dc.identifier.pmid","20082185"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21259"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","0179-7158"],["dc.title","High-Grade Acute Organ Toxicity During Preoperative Radiochemotherapy as Positive Predictor for Complete Histopathologic Tumor Regression in Multimodal Treatment of Locally Advanced Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","564"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Surgery"],["dc.bibliographiccitation.lastpage","570"],["dc.bibliographiccitation.volume","151"],["dc.contributor.author","Jo, Peter"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Hartmann, Arndt"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Müller-Dornieden, Annegret"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Schneider-Stock, Regine"],["dc.contributor.author","Gaedcke, Jochen"],["dc.date.accessioned","2018-11-07T09:11:55Z"],["dc.date.available","2018-11-07T09:11:55Z"],["dc.date.issued","2012"],["dc.description.abstract","Background. Locally advanced rectal cancers are treated with preoperative radiochemotherapy (RCT). However, subsets of patients have no benefit from preoperative treatment. Since epigenetic modifications, including DNA methylation, may influence response to neoadjuvant treatment we studied the CpG island methylator phenotype (CIMP) in patients who received a 5-fluouracil based RCT Methods. One hundred fifty patients, with locally advanced rectal cancer, treated within a phase HI clinical trial (CAO/ARO/AIO-94 and -04), were included in this analysis. CIMP was assessed by methylation specific PCR (MSP) using RUNX3, SOCS1, NEUROG1, IGF2, and CACNA1G as a marker panel. Loss of mismatch repair gene (MMR) expression was assessed by immunohistochemistry for a subset of patients. KRAS and BRAF mutation status were assessed using Sanger sequencing. Results. The CIMP status could be established in all 150 patients. Fifteen (10%) revealed CIMP positivity >= 3 methylated promoters), whereas 135 patients (90%) where classified as CIMP negative. Analysis for MMR status. did not reveal any microsatellite instability (MSI). A single mutation of the BRAF gene (D594G) was detected. The KRAS gene (exon 1, 2, and 3) was mutated in 65 tumors (43%) but was not correlated to a specific CIMP status. Three- and 5-year disease-free survival was notably worse in CIMP positive patients (56% and 0% vs 80% and 75%; P < .01) suggesting an increased likelihood of poor clinical outcome (HR 5.5; 95% CI: [2.1, 13.9]). Conclusion. CIMP positivity, defined by methylation of at least 3 specific gene promoters, is an infrequent event in locally advanced rectal cancer. However it increases the likelihood of distant metastases. Therefore, the CIMP status may be included as a molecular marker for the identification of high-risk patients and might contribute to individual treatment stratification. (Surgery 2012;151:564-70.)"],["dc.identifier.doi","10.1016/j.surg.2011.08.013"],["dc.identifier.isi","000301996600010"],["dc.identifier.pmid","22001634"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26829"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mosby-elsevier"],["dc.relation.issn","0039-6060"],["dc.title","CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","186"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Bosch, Jan"],["dc.contributor.author","Jung, K."],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Herrmann, M. K. A."],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Roedel, Ralf M. W."],["dc.date.accessioned","2018-11-07T08:43:05Z"],["dc.date.available","2018-11-07T08:43:05Z"],["dc.date.issued","2010"],["dc.format.extent","127"],["dc.identifier.isi","000278071200346"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19871"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","16th Annual Meeting of the German-Society-of-Radio-Oncology"],["dc.relation.eventlocation","Magdeburg, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","Higher grade acute organ toxicity (fflCTC grade 3) during preoperative radio (chemo) therapy as a prognostic factor in patients with local advanced, inoperable squamous cell carcinoma of the head and neck area (oral cavity, oropharynx, larynx, hypopharynx)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","185"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Herrmann, M. K."],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Jung, K."],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Christiansen, H."],["dc.date.accessioned","2018-11-07T08:29:44Z"],["dc.date.available","2018-11-07T08:29:44Z"],["dc.date.issued","2009"],["dc.format.extent","153"],["dc.identifier.isi","000268225500402"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16728"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","15th Annual Conference of the Deutschen-Gesellschaft-fur-Radioonkologie"],["dc.relation.eventlocation","Bremen, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","Comparison of Micro-nucleus and Chromosomes, but in the rational engineering Documentation cytogenetic Damage in Neoadjuvant radio-chemotherapy Rectal carcinoma patients treated"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]